Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-221 manufacturers

Filters

Filters

Filters , active

Country of origin : China
None products found

pp-221

Tablets

Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Indication: Autosomal dominant polycystic kidney disease (ADPKD) — rapidly progressive; renal oedema Clinical stage: Phase 2 — Phase 2 randomised double-blind placebo-controlled RCT for ADPKD ongoing (NCT06800651); Phase 2 dose-finding for renal oedema (NCT06670534) Modality: Small molecule (novel selective arginine vasopressin V2 receptor antagonist — NCE) Mechanism / Target: Selective vasopressin V2 receptor (V2R) antagonist; blocks vasopressin-stimulated cAMP production in renal collecting duct principal cells; reduces fluid-driven cyst formation and growth in ADPKD; long-residence-time V2R binding (claimed property improving duration of cAMP suppression vs. tolvaptan); potent aquaretic for renal oedema management Route / form: Oral tablet Differentiation: Novel V2R antagonist NCE distinct from tolvaptan; Phase 2 double-blind RCT for ADPKD (NCT06800651) and Phase 2 renal oedema study (NCT06670534) ongoing;
Manufacturer #39357

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.